Impact of Gene Polymorphism on Pharmacokinetics and Pharmaco-dynamics of Calcium Channel Blockers: A Narrative Review

  • Sarah Puspita Atmaja Faculty of Pharmacy, Universitas Kristen Immanuel. Jl. Ukrim no. km 11, Kalasan, Sleman 55571, Yogyakarta, Indonesia
  • Dwi Aris Agung Nugrahaningsih Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Sekip Utara 55281, Yogyakarta, Indonesia
  • Ellsya Angeline Rawar Faculty of Pharmacy, Universitas Kristen Immanuel. Jl. Ukrim no. km 11, Kalasan, Sleman 55571, Yogyakarta, Indonesia
  • Ani Kristiyani Faculty of Pharmacy, Universitas Kristen Immanuel. Jl. Ukrim no. km 11, Kalasan, Sleman 55571, Yogyakarta, Indonesia
  • Ahmad Hamim Sadewa Department of Biochemistry, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Sekip Utara 55281, Yogyakarta, Indonesia
  • Dita Maria Virginia Division of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Sanata Dharma, Yogyakarta, Indonesia
Keywords: calcium channel blocker, gene polymorphism, efficacy


A class of drugs known as calcium channel blockers (CCBs) is used to treat hypertension, angina, and arrhythmias. There are two subcategories of this medication class: dihydropyridines and non-dihydropyridines. Studies on CYP3A5*3, AGTR1 rs275653, ABCB1 (MDR1) rs1045642, and POR*28 A503V have all investigated the effects of SNPs on CCBs. This study will carry out more research to ascertain which SNPs have the most influence on the effectiveness of CCBs. The narrative reviews in this article come from a variety of sources. We performed searches in Pubmed, ScienceDirect, and Google Scholar using the terms "calcium channel blocker," "efficacy," "blood pressure response," "pharmacokinetic," and "polymorphism" OR "genetic" OR "genomic" to find pertinent articles. When prescription antihypertensive medications, particularly calcium channel blockers, it is important to take into account certain gene variants for example CYP3A5*3/*3, CYP3A4 *1G/*1G, MDR1 C3435T , RyR3 gene rs877087 because of their considerable effects.


Agrawal, V., Choi, J. H., Giacomini, K. M., & Miller, W. L. (2010). Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenetics and Genomics, 20(10), 611–618.
Amberg, G. C., & Navedo, M. F. (2013). Calcium Dynamics in Vascular Smooth Muscle. Microcirculation, 20(4), 281–289.
Baig, S., Joseph, S. A., Tayler, H., Abraham, R., Owen, M. J., Williams, J., … Love, S. (2010). Distribution and expression of picalm in alzheimer disease. Journal of Neuropathology and Experimental Neurology, 69(10), 1071–1077.
Baudin, B. (2005). Polymorphism in angiotensin II receptor genes and hypertension. Experimental Physiology, 90(3), 277–282.
Bhatnagar, V., Garcia, E. P., O’Connor, D. T., Brophy, V. H., Alcaraz, J., Richard, E., … Lipkowitz, M. S. (2010). CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. American Journal of Nephrology, 31(2), 95–103.
Bradwell, A., Hughes, R., & Harden, E. (2007). Atlas of HE-p 2 Patterns. Birmingham: Binding Site.
Brüning-Richardson, A., Bond, J., Alsiary, R., Richardson, J., Cairns, D. A., McCormac, L., … Bell, S. M. (2012). NuMA overexpression in epithelial ovarian cancer. PLoS ONE, 7(6), 1–11.
Burkhard, F. Z., Parween, S., Udhane, S. S., Flück, C. E., & Pandey, A. V. (2017). P450 Oxidoreductase deficiency: Analysis of mutations and polymorphisms. Journal of Steroid Biochemistry and Molecular Biology, 165(2015), 38–50.
Chandra, K. S., & Ramesh, G. (2013). The fourth-generation Calcium channel blocker: Cilnidipine. Indian Heart Journal, 65(6), 691–695.
Cheng, H., Wang, F., Ding, X., Ding, H., & Song, X. (2009). Association of PRKCH gene with lacunar infarction in a local Chinese Han population. Neuroscience Letters, 464(2), 146–149.
Do, A. N., Lynch, A. I., Claas, S. A., Boerwinkle, E., Davis, B. R., & Charles, E. (2016). The effects of genes implicated in cardiovascular disease on blood-pressure response to treatment among treatment-naïve hypertensive African Americans in the GenHAT study, 30(9), 549–554.
Dolphin, A. C. (2009). Calcium channel diversity: multiple roles of calcium channel subunits. Current Opinion in Neurobiology, 19(3), 237–244.
Dolphin, A. C. (2016). Voltage-gated calcium channels and their auxiliary subunits: physiology and pathophysiology and pharmacology. Journal of Physiology, 594(19), 5369–5390.
Durand, P., Debray, D., Kolaci, M., Bouligand, J., Furlan, V., Fabre, M., … Becquemont, L. (2013). Tacrolimus dose requirement in pediatric liver transplantation: Influence of CYP3A5 gene polymorphism. Pharmacogenomics, 14(9), 1017–1025.
Elliott, W. J., & Ram, C. V. S. (2011). Calcium channel blockers. Journal of Clinical Hypertension, 13(9), 687–689.
Feng, T., Kalyaanamoorthy, S., & Barakat, K. (2012). L-Type Calcium Channels: Structure and Functions. Intech, 13. Retrieved from
Ferrari, R., Moreno, J. H., Minhajuddin, A. T., O’Bryant, S. E., Reisch, J. S., Barber, R. C., & Momeni, P. (2012). Implication of common and disease specific variants in CLU, CR1, and PICALM. Neurobiology of Aging, 33(8), 1846.e7-1846.e18.
Filigheddu, F., Reid, J. E., Troffa, C., PinnaParpaglia, P., Argiolas, G., Testa, A., … Glorioso, N. (2004). Genetic polymorphisms of the β-adrenergic system: Association with essential hypertension and response to β-blockade. Pharmacogenomics Journal, 4(3), 154–160.
Fill, Mi., & Copello, J. A. (2012). Ryanodine receptor calcium release channels: An evolutionary perspective. Advances in Experimental Medicine and Biology, 740, 159–182.
Fischer, Z., Das, R., Shipman, A., Fan, J. Y., Pence, L., Bouyain, S., & Dobens, L. L. (2017). A Drosophila model of insulin resistance associated with the human TRIB3 Q/R polymorphism. DMM Disease Models and Mechanisms, 10(12), 1453–1464.
Flück, C. E., Mullis, P. E., & Pandey, A. V. (2010). Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism. Biochemical and Biophysical Research Communications, 401(1), 149–153.
Ghafil, F. A., Mohammad, B. I., Al-Janabi, H. S., Hadi, N. R., & Al-Aubaidy, H. A. (2019). Genetic Polymorphism of Angiotensin II Type 1 Receptors and Their Effect on the Clinical Outcome of Captopril Treatment in Arab Iraqi Patients with Acute Coronary Syndrome (Mid Euphrates). Indian Journal of Clinical Biochemistry.
Gong, I. Y., Mansell, S. E., & Kim, R. B. (2013). Absence of both MDR1 (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Transporters Significantly Alters Rivaroxaban Disposition and Central Nervous System Entry. Basic and Clinical Pharmacology and Toxicology, 112(3), 164–170.
Gong, S., Su, B. Bin, Tovar, H., Mao, C., Gonzalez, V., Liu, Y., … Xu, C. (2018). Polymorphisms Within RYR3 Gene Are Associated With Risk and Age at Onset of Hypertension , Diabetes , and Alzheimer ’ s Disease, 31(July).
GUO, C., PEI, Q., TAN, H., HUANG, Z., YUAN, H., & YANG, G. (2015). Effects of genetic factors on the pharmacokinetics and pharmacodynamics of amlodipine in primary hypertensive patients. Biomedical Reports, 3(2), 195–200.
Han, J. M., Yee, J., Chung, J. E., Lee, K. E., Park, K., & Gwak, H. S. (2020). Effects of cytochrome P450 oxidoreductase genotypes on the pharmacokinetics of amlodipine in healthy Korean subjects. Molecular Genetics and Genomic Medicine, 8(5), 1–10.
He, F., Luo, J., Luo, Z., Fan, L., He, Y., Zhu, D., … Zhang, W. (2013). The KCNH2 Genetic Polymorphism (1956, C>T) Is a Novel Biomarker That Is Associated with CCB and α,β-ADR Blocker Response in EH Patients in China. PLoS ONE, 8(4).
He, F., Sun, B., Li, L., Liu, M., Lin, W., Liu, L., … Zhou, Z. (2020). TRIB3 rs6037475 is a potential biomarker for predicting felodipine drug response in Chinese patients with hypertension. Annals of Translational Medicine, 8(7), 437–437.
He, F. Z., McLeod, H. L., & Zhang, W. (2013). Current pharmacogenomic studies on hERG potassium channels. Trends in Molecular Medicine, 19(4), 227–238.
Hedley, P. L., Jørgensen, P., Schlamowitz, S., Moolman-Smook, J., Kanters, J. K., Corfield, V. A., & Christiansen, M. (2009). The genetic basis of brugada syndrome: A mutation update. Human Mutation, 30(9), 1256–1266.
Hira, D., & Terada, T. (2018). BCRP/ABCG2 and high-alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical implications. Biochemical Pharmacology, 147, 201–210.
Hodges, L. M., Markova, S. M., Chinn, L. W., Gow, J. M., Kroetz, D. L., Klein, T. E., & Altman, R. B. (2012). Very Important Pharmacogene Summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics., 21(3), 152–161.
Hong, G. L., Chen, X. Z., Liu, Y., Liu, Y. H., Fu, X., Lin, S. B., & Zhu, Q. (2013). Genetic variations in MOV10 and CACNB2 are associated with hypertension in a Chinese Han population. Genetics and Molecular Research, 12(4), 6220–6227.
Huang, Y., Wen, G., Lu, Y., Wen, J., Ji, Y., Xing, X., … Yuan, H. (2017). CYP3A4∗1G and CYP3A5∗3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation. International Journal of Clinical Pharmacology and Therapeutics, 55(2), 109–118.
Huh, J. Y., Chung, S., Oh, D., Kang, M. S., Eom, H. S., Cho, E. H., … Kong, S. Y. (2010). Clathrin assembly lymphoid myeloid leukemia-AF10-positive acute leukemias: A report of 2 cases with a review of the literature. Korean Journal of Laboratory Medicine, 30(2), 117–121.
Hussain, S., Singh, A., Rahman, S. O., Habib, A., & Najmi, A. K. (2018). Calcium channel blocker use reduces incident dementia risk in elderly hypertensive patients: A meta-analysis of prospective studies. Neuroscience Letters, 671, 120–127.
Ieiri, I., Takane, H., & Otsubo, K. (2004). The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clinical Pharmacokinetics, 43(9), 553–576.
Jiang, S., Hsu, Y. H., Venners, S. A., Zhang, Y., Xing, H., Wang, X., & Xu, X. (2011). Interactive effect of angiotensin II type 1 receptor (AGT1R) polymorphisms and plasma irbesartan concentration on antihypertensive therapeutic responses to irbesartan. Journal of Hypertension, 29(5), 890–895.
Johnson, R., Dludla, P., Mabhida, S., Benjeddou, M., Louw, J., & February, F. (2019). Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension: a mini review. Heart Failure Reviews, 24(3), 343–357.
Kamide, K., Asayama, K., Katsuya, T., Ohkubo, T., Hirose, T., Inoue, R., … Imai, Y. (2013). Genome-wide response to antihypertensive medication using home blood pressure measurements: a pilot study nested within the HOMED-BP study. Pharmacogenomics, 14(14), 1709–1721. Retrieved from
Khatri, R., Kulick, N., Rementer, R. J. B., Fallon, J. K., Sykes, C., Schauer, A. P., … Lee, C. R. (2021). Pregnancy-Related Hormones Increase Nifedipine Metabolism in Human Hepatocytes by Inducing CYP3A4 Expression. Journal of Pharmaceutical Sciences, 110(1), 412–421.
Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J. J., Roden, D. M., & Wilkinson, G. R. (1998). The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. Journal of Clinical Investigation, 101(2), 289–294.
Kitzmiller, J. P., Luzum, J. A., Baldassarre, D., Krauss, R. M., & Medina, M. W. (2014). CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort. Pharmacogenetics and Genomics, 24(10), 486–491.
Kiyomitsu, T., & Boerner, S. (2021). The Nuclear Mitotic Apparatus (NuMA) Protein: A Key Player for Nuclear Formation, Spindle Assembly, and Spindle Positioning. Frontiers in Cell and Developmental Biology, 9(April), 1–12.
Klenke, S., & Siffert, W. (2011). SNPs in genes encoding G proteins in pharmacogenetics. Pharmacogenomics, 12(5), 633–654.
Koo, D. H., Ryu, M. H., Ryoo, B. Y., Beck, M. Y., Na, Y. S., Shin, J. G., … Kang, Y. K. (2015). Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor. Cancer Chemotherapy and Pharmacology, 75(1), 173–182.
Kvehaugen, A. S., Melien, Ø., Holmen, O. L., Laivuori, H., Dechend, R., & Staff, A. C. (2014). Hypertension after preeclampsia and relation to the C1114G polymorphism (rs4606) in RGS2: Data from the Norwegian HUNT2 study. BMC Medical Genetics, 15(1), 1–10.
Lajemi, M., Labat, C., Gautier, S., Lacolley, P., Safar, M., Asmar, R., … Benetos, A. (2001). Angiotensin II type 1 receptor-153A/G and 1166A/C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects. Journal of Hypertension, 19(3), 407–413.
Lamba, J., Hebert, J. M., Schietz, E. G., Klein, T. E., & Altman, R. B. (2016). PharmGKB summary: Very important pharmacogene information for MT-RNR1. Pharmacogenetics and Genomics, 26(12), 558–567.
Lanner, J. T., Georgiou, D. K., Joshi, A. D., & Hamilton, S. L. (2010). Ryanodine Receptors: Structure, Expression, Molecular Details, and Function in Calcium Release. Cold Spring Harbor Perspectives in Biology, 2, 1–21. Retrieved from
Laurent, S. (2017). Antihypertensive drugs. Pharmacological Research, 124, 116–125.
Li, F., Hu, S., Zhou, X., Mei, X., & Zhou, Y. (2020). Association between R353Q (rs6046) polymorphism in factor VII with coronary heart disease a meta-analysis. International Heart Journal, 61(4), 641–650.
Li, J., Shi, J., Huang, W., Sun, J., Wu, Y., Duan, Q., … Lange, E. M. (2015). Variant near FGF5 has stronger effects on blood pressure in Chinese with a higher body mass index. American Journal of Hypertension, 28(8), 1031–1037.
Li, Y. yan, Wang, H., & Zhang, Y. yang. (2021). FVII gene R353Q polymorphism and coronary heart disease: a meta-analysis including 3258 subjects. Journal of Thrombosis and Thrombolysis, 52(1), 324–330.
Liew, S. C., & Gupta, E. Das. (2015). Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: Epidemiology, metabolism and the associated diseases. European Journal of Medical Genetics, 58(1), 1–10.
Lin, Y., Lai, X., Chen, B., Xu, Y., Huang, B., Chen, Z., … Chen, G. (2011). Genetic variations in CYP17A1, CACNB2 and PLEKHA7 are associated with blood pressure and/or hypertension in she ethnic minority of China. Atherosclerosis, 219(2), 709–714.
Luu, A., Waldschmidt, R., Guisinger, T., Seeley, S., D’Souza, M., & Chrissobolis, S. (2022). Deletion of RGS2 Results in Increased Blood Pressure and Depression-Like Behavior in the Presence of Elevated Ang II Levels in Female Mice. The FASEB Journal, 36(S1).
Lynch, A. I., Irvin, M. R., Boerwinkle, E., Davis, B. R., Vaughan, L. K., Ford, C. E., … Shrestha, S. (2013). RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment. Physiology & Behavior, 176(5), 139–148.
M, D., Quinney, K. S., Clay, M. J., Renbarger, L. J., Hebert, F. M., Clark, S., … Caritis, N. S. (2014). Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic. Exp Biol Med, 239(11), 1476–1488.
Mannino, G. C., Averta, C., Fiorentino, T. V., Succurro, E., Spiga, R., Mancuso, E., … Sesti, G. (2021). The TRIB3 R84 variant is associated with increased left ventricular mass in a sample of 2426 White individuals. Cardiovascular Diabetology, 20(1), 1–8.
Mao, Q., & Unadkat, J. D. (2015). Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update. AAPS Journal, 17(1), 65–82.
Mayer, U., Wagenaar, E., Beijnen, J. H., Smit, J. W., Meijer, D. K. F., Van Asperen, J., … Schinkel, A. H. (1996). Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdrla P-glycoprotein. British Journal of Pharmacology, 119(5), 1038–1044.
Meibohm, B., Beierle, I., & Derendorf, H. (2002). How important are gender differences in pharmacokinetics? Clinical Pharmacokinetics, 41(5), 329–342.
Miller, W. L., Agrawal, V., Sandee, D., Tee, M. K., Huang, N., Choi, J. H., … Giacomini, K. M. (2011). Consequences of POR mutations and polymorphisms. Molecular and Cellular Endocrinology, 336(1–2), 174–179.
Miller, W. L., Huang, N., Agrawal, V., & Giacomini, K. M. (2009). Genetic variation in human P450 oxidoreductase. Molecular and Cellular Endocrinology, 300(1–2), 180–184.
Miranda, W. E., DeMarco, K. R., Guo, J., Duff, H. J., Vorobyov, I., Clancy, C. E., & Noskov, S. Y. (2020). Selectivity filter modalities and rapid inactivation of the hERG1 channel. Proceedings of the National Academy of Sciences of the United States of America, 117(6), 2795–2804.
Nance, M. R., Kreutz, B., Tesmer, V. M., Sterne-Marr, R., Kozasa, T., & Tesmer, J. J. G. (2013). Structural and functional analysis of the regulator of G protein signaling 2-Gαq complex. Structure, 21(3), 438–448.
Newton-Cheh, C., Johnson, T., Gateva, V., Tobin, M. D., Bochud, M., Coin, L., … Wichmann, H. E. (2009). Eight blood pressure loci identified by genome-wide association study of 34,433 people of European ancestry. Nature Genetics, 41(6), 666–676.
Niu, Y., Gong, Y., Langaee, T. Y., Davis, H. M., Elewa, H., Beitelshees, A. L., … Johnson, J. A. (2010). Genetic variation in the β2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the international verapamil SR-trandolapril study genetic substudy (INVEST-GENES). Circulation: Cardiovascular Genetics, 3(6), 548–555.
Ornitz, D. M., & Itoh, N. (2001). Protein family review: Fibroblast growth factors. Genome Biology, 2(3), reviews3005.1-3005.12. Retrieved from
Ornitz, D. M., & Itoh, N. (2015). The fibroblast growth factor signaling pathway. Wiley Interdisciplinary Reviews: Developmental Biology, 4(3), 215–266.
Osei-Owusu, P., & Blumer, K. J. (2015). Regulator of G Protein Signaling 2: A Versatile Regulator of Vascular Function. Progress in Molecular Biology and Translational Science (1st ed., Vol. 133). Elsevier Inc.
Oshiroa, C., Thorna, C. F., Rodenc, D. M., Kleina, T. E., & Altman, R. B. (2010). KCNH2 pharmacogenomics summary. Pharmacogenet Genomics., 23(1), 1–7.
Pandey, A. V., & Sproll, P. (2014). Pharmacogenomics of human P450 oxidoreductase. Frontiers in Pharmacology, 5 MAY(May), 1–11.
Parchwani, D. N., Patel, D. D., Rawtani, J., & Yadav, D. (2018). Analysis of Association of Angiotensin II Type 1 Receptor Gene A1166C Gene Polymorphism with Essential Hypertension. Indian Journal of Clinical Biochemistry, 33(1), 53–60.
Peters, R., Booth, A., & Peters, J. (2014). A systematic review of calciumchannel blocker use and cognitive decline/dementia in the elderly. Journal of Hypertension, 32(10), 1945–1958.
Prudente, S., Hribal, M. L., Flex, E., Turchi, F., Morini, E., De Cosmo, S., … Trischitta, V. (2005). The functional Q84R polymorphism of mammalian tribbles homolog TRB3 is associated with insulin resistance and related cardiovascular risk in Caucasians from Italy. Diabetes, 54(9), 2807–2811.
Prudente, S., Sesti, G., Pandolfi, A., Andreozzi, F., Consoli, A., & Trischitta, V. (2012). The mammalian tribbles homolog TRIB3, glucose homeostasis, and cardiovascular diseases. Endocrine Reviews, 33(4), 526–546.
Prudente, S., & Trischitta, V. (2015). The TRIB3 Q84R polymorphism, insulin resistance and related metabolic alterations. Biochemical Society Transactions, 43, 1108–1111.
Punzallan, F. E. R., Cutiongco, E. M. C., Nevado, J. J. B., Magno, J. D. A., Ona, D. I. D., Yvonne, A., … Agustin, C. F. (2022). The rs1458038 variant near FGF5 is associated with poor response to calcium channel blockers among Filipinos. Medicine, 5(March 2021).
Raponi, M., & Baralle, D. (2010). Alternative splicing: Good and bad effects of translationally silent substitutions: Minireview. FEBS Journal, 277(4), 836–840.
Ren, Y., Jiao, X., & Zhang, L. (2018). Expression level of fibroblast growth factor 5 (FGF5) in the peripheral blood of primary hypertension and its clinical significance. Saudi Journal of Biological Sciences, 25(3), 469–473.
Rosskopf, D., Busch, S., Manthey, I., & Siffert, W. (2000). G protein β3 gene: Structure, promoter, and additional polymorphisms. Hypertension, 36(1), 33–41.
Rosskopf, D., Manthey, I., & Siffert, W. (2002). Identification and ethnic distribution of major haplotypes in the gene GNB3 encoding the G-protein β3 subunit. Pharmacogenetics, 12(3), 209–220.
Saiz-Rodríguez, M., Almenara, S., Navares-Gómez, M., Ochoa, D., Román, M., Zubiaur, P., … Abad-Santos, F. (2020). Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates. Biomedicines, 8(4).
Sanguinetti, M. C. (2010). HERG1 channelopathies. Pflugers Archiv European Journal of Physiology, 460(2), 265–276.
Sarzani, R., Pietrucci, F., Corinaldesi, C., Francioni, M., Letizia, C., D’Erasmo, E., … Rappelli, A. (2006). The functional HERG variant 897T is associated with Conn’s adenoma. Journal of Hypertension, 24(3), 479–487.
Schelleman, H., Stricker, B. H. C., Verschuren, W. M. M., de Boer, A., Kroon, A. A., de Leeuw, P. W., … Klungel, O. H. (2006). Interactions between five candidate genes and antihypertensive drug therapy on blood pressure. Pharmacogenomics Journal, 6(1), 22–26.
Semianiv, M. M., Sydorchuk, L. P., Dzhuryak, V. S., Gerush, O. V., Vasylovich Gerush, O., Palamar, A. O., … Sydorchuk, R. I. (2021). Association of AGTR1 (rs5186), VDR (rs2228570) genes polymorphism with blood pressure elevation in patients with essential arterial hypertension. Journal of Medicine and Life, 14(6), 782–789.
Sica, D. A. (2005). Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics. Journal of Clinical Hypertension (Greenwich, Conn.), 7(4 Suppl 1), 21–26.
Smith, N., Chen, M.-H., Dehghan, A., Strachan, D. P., Basu, S., Soranzo, N., … Rudan, I. (2011). Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE Consortium. Circulation, 121(12), 1382–1392.
Song, Y., Lim, H. H., Yee, J., Yoon, H. Y., & Gwak, H. S. (2022). The Association between ABCG2 421C>A (rs2231142) Polymorphism and Rosuvastatin Pharmacokinetics: A Systematic Review and Meta-Analysis. Pharmaceutics, 14(3).
Spark, C. A., Bangs, P. L., McNeil, G. P., Lawrence, J. B., & Fey, E. G. (1993). Assignment of Nuclear Mitotic Apparatus Protein NuMA Gene to Human Chromosome 11q13. Genomics.
Sugimoto, K., Katsuya, T., Kamide, K., Fujisawa, T., Shimaoka, I., Ohishi, M., … Rakugi, H. (2010). Promoter polymorphism of rgs2 gene is associated with change of blood pressure in subjects with antihypertensive treatment: The azelnidipine and temocapril in hypertensive patients with type 2 diabetes study. International Journal of Hypertension, 2010.
Sun, F., Chen, Z., Yao, P., Weng, B., Liu, Z., & Cheng, L. (2021). Meta-Analysis of ABCG2 and ABCB1 Polymorphisms With Sunitinib-Induced Toxicity and Efficacy in Renal Cell Carcinoma. Frontiers in Pharmacology, 12(March), 1–14.
Sychev, D., Shikh, N., Morozova, T., Grishina, E., Ryzhikova, K., & Malova, E. (2018). Effects of ABCB1 rs1045642 polymorphisms on the efficacy and safety of amlodipine therapy in caucasian patients with stage I–II hypertension. Pharmacogenomics and Personalized Medicine, 11, 157–165.
Tomaschitz, A., Pilz, S., Ritz, E., Obermayer-Pietsch, B., & Pieber, T. R. (2010). Aldosterone and arterial hypertension. Nature Reviews Endocrinology, 6(2), 83–93.
Tornio, A., & Backman, J. T. (2018). Cytochrome P450 in Pharmacogenetics: An Update. Advances in Pharmacology (1st ed., Vol. 83). Elsevier Inc.
Türkmen, D., Masoli, J. A. H., Delgado, J., Kuo, C.-L., Bowden, J., Melzer, D., & Pilling, L. C. (2022). Calcium Channel Blockers: clinical outcome associations with pharmacogenetics variants in 32,000 patients, 1–15.
Turner, S. T., Schwartz, G. L., Chapman, A. B., & Boerwinkle, E. (2001). C825T Polymorphism of the G Protein ␤3 -Subunit and Antihypertensive Response to a Thiazide Diuretic, 739–743. Retrieved from
Ueno, K., & Sato, H. (2012). Sex-related differences in pharmacokinetics and pharmacodynamics of anti-hypertensive drugs. Hypertension Research, 35(3), 245–250.
Van Petegem, F. (2012). Ryanodine receptors: Structure and function. Journal of Biological Chemistry, 287(38), 31624–31632.
Weinstein, L. S., Chen, M., Xie, T., & Liu, J. (2006). Genetic diseases associated with heterotrimeric G proteins. Trends in Pharmacological Sciences, 27(5), 260–266.
Werk, A. N., & Cascorbi, I. (2014). Functional gene variants of CYP3A4. Clinical Pharmacology and Therapeutics, 96(3), 340–348.
Wilson, C. P., McNulty, H., Ward, M., Strain, J. J., Trouton, T. G., Hoeft, B. A., … Scott, J. M. (2013). Blood pressure in treated hypertensive individuals with the mthfr 677tt genotype is responsive to intervention with riboflavin: Findings of a targeted randomized trial. Hypertension, 61(6), 1302–1308.
Wilson, C. P., Ward, M., McNulty, H., Strain, J. J., Trouton, T. G., Horigan, G., … Scott, J. M. (2012). Riboflavin offers a targeted strategy for managing hypertension in patients with the MTHFR 677TT genotype: A 4-y follow-up. American Journal of Clinical Nutrition, 95(3), 766–772.
Wolking, S., Schaeffeler, E., Lerche, H., Schwab, M., & Nies, A. T. (2015). Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature. Clinical Pharmacokinetics, 54(7), 709–735.
Wu, C. L., & Wen, S. H. (2016). A 10-year follow-up study of the association between calcium channel blocker use and the risk of dementia in elderly hypertensive patients. Medicine (United States), 95(32).
Wu, H., Wang, B., Ban, Q., Chen, L., Yan, D., Yu, Y., … Xu, X. (2018). Association of total homocysteine with blood pressure in a general population of Chinese adults: A cross-sectional study in Jiangsu province, China. BMJ Open, 8(6), 1–8.
Wu, Y. Le, Hu, C. Y., Lu, S. S., Gong, F. F., Feng, F., Qian, Z. Z., … Sun, Y. H. (2014). Association between methylenetetrahydrofolate reductase (MTHFR) C677T/A1298C polymorphisms and essential hypertension: A systematic review and meta-analysis. Metabolism: Clinical and Experimental, 63(12), 1503–1511.
Xiang, Q., Li, C., Zhao, X., & Cui, Y. M. (2017). The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers. Journal of Clinical Pharmacy and Therapeutics, 42(3), 345–349.
Xu, H., Zheng, H., Shen, Y., Huang, J., & Luo, M. (2012). Polymorphism of the methylenetetrahydrofolate reductase gene C677T and its influence on the antihypertensive and vascular protective effects of short-term lercanidipine treatment. Gene, 500(2), 207–210.
Xuan, C., Bai, X. Y., Gao, G., Yang, Q., & He, G. W. (2011). Association between polymorphism of methylenetetrahydrofolate reductase (MTHFR) C677T and risk of myocardial infarction: A meta-analysis for 8,140 cases and 10,522 controls. Archives of Medical Research, 42(8), 677–685.
Yamada, Y., Ando, F., & Shimokata, H. (2008). Association of the genetic variants of APOA5 and PRKCH with hypertension in community-dwelling Japanese individuals. Molecular Medicine Reports, 1(3), 407–414.
Yu, Q., Gao, F., & Ma, X. L. (2011). Insulin says NO to cardiovascular disease. Cardiovascular Research, 89(3), 516–524.
Yun, Y. R., Won, J. E., Jeon, E., Lee, S., Kang, W., Jo, H., … Kim, H. W. (2010). Fibroblast growth factors: Biology, function, and application for tissue regeneration. Journal of Tissue Engineering, 1(1), 1–18.
Zeng, C. (2000). NuMA: A nuclear protein involved in mitotic centrosome function. Microscopy Research and Technique, 49(5), 467–477.<467::AID-JEMT9>3.0.CO;2-V
Zeng, L., Webster, S. V., & Newton, P. M. (2012). The biology of protein kinase C. Advances in Experimental Medicine and Biology, 740, 639–661.
Zhang, C., Wang, L., Liao, Q., Zhang, L., Xu, L., Chen, C., … Duan, S. (2013). Genetic associations with hypertension: Meta-analyses of six candidate genetic variants. Genetic Testing and Molecular Biomarkers, 17(10), 736–742.
Zhang, H., Chen, M., Wang, X., & Yu, S. (2017). Patients with CYP3A4∗1G genetic polymorphism consumed significantly lower amount of sufentanil in general anesthesia during lung resection. Medicine (United States), 96(4), 2016–2018.
Zhang, P., & Mende, U. (2014). Functional role, mechanisms of regulation, and therapeutic potential of regulator of G protein signaling 2 in the heart. Trends in Cardiovascular Medicine, 24(2), 85–93.
Zhang, Q., Chen, J., Qin, Y., Wang, J., & Zhou, L. (2018). Mutations in voltage-gated L-type calcium channel: Implications in cardiac arrhythmia. Channels, 12(1), 201–218.
Zhang, Wei, Chang, Y. Z., Kan, Q. C., Zhang, L. R., Li, Z. S., Lu, H., … Zhang, J. (2010). CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients. European Journal of Clinical Pharmacology, 66(1), 61–66.
Zhang, Weiwei, Yang, Z., Li, X., Wen, J., Zhang, H., Wang, S., … Su, Q. (2015). The functional Q84R polymorphism of TRIB3 gene is associated with diabetic nephropathy in Chinese type 2 diabetic patients. Gene, 555(2), 357–361.
Zhang, X., Fu, L., Zhang, Q., Yan, L., Ma, Y., Tu, B., … Qiao, J. (2011). Association of TRB3 Q84R polymorphism with polycystic ovary syndrome in Chinese women. Reproductive Biology and Endocrinology, 9, 3–9.
Zhang, Zan Lin, Li, H. L., Wen, Z. P., Yang, G. P., Zhang, W., & Chen, X. P. (2016). Influence of G-protein β-Polypeptide 3 C825T polymorphism on antihypertensive response to telmisartan and amlodipine in Chinese patients. Chinese Medical Journal, 129(1), 8–14.
Zhang, Zan Ling, Zhu, M. M., Li, H. L., Shi, L. H., Chen, X. P., Luo, J., & Zhao, J. F. (2017). Influence of PRKCH gene polymorphism on antihypertensive response to amlodipine and telmisartan. Clinical and Experimental Hypertension, 39(8), 726–731.
Zheng, H., Xu, H., Cui, B., Xie, N., Wang, Z., & Luo, M. (2013). Association between polymorphism of the G-protein β3 subunit C825T and essential hypertension: An updated meta-analysis involving 36,802 subjects. Biological Research, 46(3), 265–273.
Zhou, J., He, F., Sun, B., Liu, R., Gao, Y., Ren, H., … Zhang, W. (2019). Polytropic Influence of TRIB3 rs2295490 Genetic Polymorphism on Response to Antihypertensive Agents in Patients With Essential Hypertension. Frontiers in Pharmacology, 10(March), 1–10.
Zhou, L. P., Yao, F., Luan, H., Wang, Y. L., Dong, X. H., Zhou, W. W., & Wang, Q. H. (2013). CYP3A4*1B polymorphism and cancer risk: A HuGE review and meta-analysis. Tumor Biology, 34(2), 649–660.
Zhou, L. Y., Zuo, X. C., Chen, K., Wang, J. L., Chen, Q. J., Zhou, Y. N., … Ming, Y. Z. (2016). Significant impacts of CYP3A4∗1G and CYP3A5∗3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients. Journal of Clinical Pharmacy and Therapeutics, 41(3), 341–347.
Zhou, S., Tao, M., Wang, Y., Wang, L., Xie, L., Chen, J., … Aa, J. (2019). Effects of CYP3A4*1G and CYP3A5*3 polymorphisms on pharmacokinetics of tylerdipine hydrochloride in healthy Chinese subjects. Xenobiotica, 49(3), 375–380.
Zhou, Y., Ingelman-Sundberg, M., & Lauschke, V. M. (2017). Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects. Clinical Pharmacology and Therapeutics, 102(4), 688–700.
Zisaki, A., Miskovic, L., & Hatzimanikatis, V. (2014). Antihypertensive Drugs Metabolism: An Update to Pharmacokinetic Profiles and Computational Approaches. Current Pharmaceutical Design, 21(6), 806–822.
Zuo, X. C., Zhang, W. L., Yuan, H., Barrett, J. S., Hua, Y., Huang, Z. J., … Yang, G. P. (2014). ABCB1 polymorphism and gender affect the pharmacokinetics of amlodipine in Chinese patients with essential hypertension: A population analysis. Drug Metabolism and Pharmacokinetics, 29(4), 305–311.
How to Cite
Atmaja, S. P., Nugrahaningsih, D. A. A., Rawar, E. A., Ani Kristiyani, Sadewa, A. H., & Virginia, D. M. (2023). Impact of Gene Polymorphism on Pharmacokinetics and Pharmaco-dynamics of Calcium Channel Blockers: A Narrative Review. Indonesian Journal of Pharmacy, 34(3).
Review Article